The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Plasma protein binding: From discovery to development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Smith, D. A., Di, L., & Kerns, E. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3287 · Cited by 898
Changes in plasma protein binding have little clinical relevance
Benet, L. Z., & Hoener, B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121829 · Cited by 825
Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients
Staatz, C. E., & Tett, S. E. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746010-00002 · Cited by 602
Predicting plasma protein binding of drugs: a new approach
Kratochwil, N. A., Huber, W., Müller, F., Kansy, M., & Gerber, P. R. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01074-2 · Cited by 553
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Doran, A., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001230 · Cited by 443
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
Weisiger, R., Gollan, J., & Ockner, R. (1981) · Science · doi:10.1126/science.6258226 · Cited by 382
HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡
Israili, Z. H., & Dayton, P. G. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-100104402 · Cited by 367
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348
Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC
Mueller, M., de la Peña, A., & Derendorf, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.369-377.2004 · Cited by 304
Summerfield, S. G., Read, K., Begley, D. J., Obradovic, T., Hidalgo, I. J., Coggon, S., Lewis, A. V., Porter, R. A., & Jeffrey, P. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121525 · Cited by 283
Kalvass, J. C., Maurer, T. S., & Pollack, G. M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012294 · Cited by 227
Gambacorti-Passerini, C. B., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P. E., Pogliani, E., et al. (2003) · PubMed · Cited by 226
Maurer, T. S., DeBartolo, D. B., Tess, D. A., & Scott, D. O. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001222 · Cited by 214
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 200
Lin, K., Perni, R. B., Kwong, A. D., & Lin, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1813-1822.2006 · Cited by 200
CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Lin, J. (2008) · Current Drug Metabolism · doi:10.2174/138920008783331077 · Cited by 187
Kalvass, J. C., Olson, E. R., Cassidy, M. P., Selley, D. E., & Pollack, G. M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119560 · Cited by 161
Biodistribution and Plasma Protein Binding of Zoledronic Acid
Weiss, H. M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A., & Schran, H. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021071 · Cited by 160
Clinical Pharmacokinetics of Cimetidine
Somogyi, A. A., & Gugler, R. (1983) · Clinical Pharmacokinetics · doi:10.2165/00003088-198308060-00001 · Cited by 156
Influence of Race or Ethnicity on Pharmacokinetics of Drugs
Johnson, J. A. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9702168 · Cited by 142
Smith, D. A., & Obach, R. S. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800415j · Cited by 139
Wendt, M. D., Wang, S., Kunzer, A. R., McClellan, W. J., Bruncko, M., Oost, T. K., Ding, H., Joseph, M. K., Zhang, H., Nimmer, P. M., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050754u · Cited by 138
SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING
Smith, D. A., & Obach, R. S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005041 · Cited by 138
Distribution of Cyclosporin in Organ Transplant Recipients
Akhlaghi, F., & Trull, A. K. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00001 · Cited by 126
Boström, E., Hammarlund‐Udenaes, M., & Simonsson, U. S. H. (2008) · Anesthesiology · doi:10.1097/aln.0b013e318164cf9e · Cited by 122
Buerger, C., Plock, N., Dehghanyar, P., Joukhadar, C., & Kloft, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01468-05 · Cited by 122
Duan, J. J. ‐., Chen, L., Wasserman, Z. R., Lu, Z., Liu, R., Covington, M. B., Qian, M., Hardman, K. D., Magolda, R. L., Newton, R. C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255670 · Cited by 120
Edmondson, S. D., Mastracchio, A., Mathvink, R. J., He, J., Harper, B., Park, Y., Beconi, M. G., Salvo, J. D., Eiermann, G. J., He, H., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060015t · Cited by 120
Receptor Occupancy and Brain Free Fraction
Watson, J. M., Wright, S., Lucas, A. J., Clarke, K. L., Viggers, J., Cheetham, S. C., Jeffrey, P., Porter, R. A., & Read, K. D. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022814 · Cited by 120
Factors affecting variability in distribution of tacrolimus in liver transplant recipients
Zahir, H., McCaughan, G. W., Gleeson, M., Nand, R. A., & McLachlan, A. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02008.x · Cited by 118
Prediction of the volumes of distribution of basic drugs in humans based on data from animals
Sawada, Y., Hanano, M., Sugiyama, Y., Harashima, H., & Iga, T. (1984) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059554 · Cited by 117
Sawada, Y., Hanano, M., Sugiyama, Y., & Iga, T. (1984) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061720 · Cited by 117
Improved measurement of drug exposure in the brain using drug-specific correction for residual blood
Fridén, M., Ljungqvist, H., Middleton, B., Bredberg, U., & Hammarlund-Udenaes, M. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.200 · Cited by 114
Current perspective of TACE inhibitors: A review
DasGupta, S., Murumkar, P. R., Giridhar, R., & Yadav, M. R. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.11.067 · Cited by 114
Plasma Protein Binding Affinity and Its Relationship to Molecular Structure: An In-silico Analysis
Gleeson, M. P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060981b · Cited by 107
Concentration-Effect Relationships of Valproic Acid
Chadwick, D. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510020-00003 · Cited by 104
Protein Binding Displacement Interactions and their Clinical Importance
McElnay, J. C., & Pf, D. (1983) · Drugs · doi:10.2165/00003495-198325050-00003 · Cited by 102
Hammarlund‐Udenaes, M. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00517.x · Cited by 95
Borthwick, A. D., Liddle, J., Davies, D. E., Exall, A. M., Hamlett, C. C. F., Hickey, D. M. B., Mason, A. M., Smith, I. E. D., Nerozzi, F., Peace, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201287w · Cited by 90
Li, J., Brahmer, J. R., Messersmith, W. A., Hidalgo, M. M., & Baker, S. D. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-5269-2 · Cited by 89
Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding.
Jones, D. R., Hall, S. D., Jackson, E. K., Branch, R. A., & Wilkinson, G. R. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24108-8 · Cited by 88
Protein Binding Drug Displacement Interactions
MacKichan, J. J. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916020-00001 · Cited by 87
Ito, K., Chiba, K., Horikawa, M., Ishigami, M., Mizuno, N., Aoki, J., Gotoh, Y., Iwatsubo, T., Kanamitsu, S.-I., Kato, M., et al. (2002) · AAPS PharmSci · doi:10.1208/ps040425 · Cited by 86
Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Lin, J. H. (2005) · Current Drug Metabolism · doi:10.2174/138920006774832578 · Cited by 85
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
McKerrecher, D., Allen, J. V., Caulkett, P. W. R., Donald, C. S., Fenwick, M. L., Grange, E., Johnson, K. M., Johnstone, C., Jones, C. D., Pike, K. G., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.022 · Cited by 85
Yang, Y., Severin, A. I., Chopra, R., Krishnamurthy, G., Singh, G., Hu, W. K., Keeney, D. R., Svenson, K., Petersen, P. J., Labthavikul, P., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.556-564.2006 · Cited by 83
Methodologies to Assess Brain Drug Delivery in Lead Optimization
Hammarlund‐Udenaes, M., Bredberg, U., & Fridén, M. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609787521607 · Cited by 82
Tissue Binding versus Plasma Binding of Drugs: General Principles and Pharmacokinetic Consequences
Fichtl, B., von Nieciecki, A., & Walter, K. (1991) · Advances in Drug Research · doi:10.1016/b978-0-12-013320-8.50006-x · Cited by 80
Targeted chronic myeloid leukemia therapy: Seeking a cure
Fausel, C. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070482 · Cited by 79
Mimoz, O., Rolland, D., Adoun, M., Marchand, S., Breilh, D., Brumpt, I., Debaene, B., & Couet, W. R. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0136-3 · Cited by 78
Comparative pharmacokinetics of benzodiazepines in dog and man
Boxenbaum, H. G. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065172 · Cited by 78
Bilello, J. A., Bilello, P., Stellrecht, K. A., Leonard, J. M., Norbeck, D. W., Kempf, D. J., Robins, T., & Drusano, G. L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1491 · Cited by 78
Diazepam and lidocaine plasma protein binding in renal disease
Grossman, S. H., Davis, D., Kitchell, B. B., et al. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.45 · Cited by 77
Drug-Protein Binding and Blood-Brain Barrier Permeability
Tanaka, H., & MIZOJIRI, K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38041-3 · Cited by 77
Salicylate clearance, the resultant of protein binding and metabolism
Furst, D. E., Tozer, T. N., & Melmon, K. L. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979263380 · Cited by 76
Liu, X., Vilenski, O., Kwan, J., Apparsundaram, S., & Weikert, R. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026674 · Cited by 75
Boselli, E., Breilh, D., Saux, M., Gordien, J.-B., & Allaouchiche, B. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0401-5 · Cited by 74
Fuse, E., Tanii, H., TAKAI, K., Asanome, K., Kurata, N., Kobayashi, H., Kuwabara, T., Kobayashi, S., & Sugiyama, Y. (1999) · PubMed · Cited by 72
Zahir, H., McCaughan, G. W., Gleeson, M., Nand, R. A., & McLachlan, A. J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200410000-00008 · Cited by 69
Walker, D. K., Brady, J., Dalvie, D., Davis, J. D., Dowty, M. E., Duncan, J. N., Nedderman, A., Obach, R. S., & Wright, P. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900213j · Cited by 67
Fukuda, H., Ohashi, R., Tsuda-Tsukimoto, M., & Tamai, I. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019026 · Cited by 67
Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human
Paulson, S. K., Kaprak, T. A., Gresk, C. J., Fast, D. M., Baratta, M. T., Burton, E. G., Breau, A. P., & Karim, A. (1999) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199909)20:6 · Cited by 66
Edwards, J. E., Brouwer, K. R., & McNamara, P. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2284-2286.2002 · Cited by 63
Li, Y.-W., Hill, G. R., Wong, H. H., Kelly, N., Ward, K., Pierdomenico, M., Ren, S. X., Gilligan, P. J., Grossman, S. J., Trainor, G. L., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045914 · Cited by 61
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors
Pevarello, P., Fancelli, D., Vulpetti, A., Amici, R., Villa, M., Pittalà, V., Vianello, P., Cameron, A. D., Ciomei, M., Mercurio, C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.071 · Cited by 57
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients
Villarroel, M. C., Pratz, K. W., Xu, L., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9767-5 · Cited by 55
Morse, G. D., Catanzaro, L. M., & Acosta, E. P. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70436-4 · Cited by 55
Zsila, F., Fitos, I., Bencze, G., Kéri, G., & Őrfi, L. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788682191 · Cited by 55
High-throughput determination of the free fraction of drugs strongly bound to plasma proteins
Schuhmacher, J., Kohlsdorfer, C., Bühner, K., Brandenburger, T., & Kruk, R. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10588 · Cited by 53
Selective plasma protein binding of antimalarial drugs to α1-acid glycoprotein
Zsila, F., Visy, J., Mády, G., & Fitos, I. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.01.053 · Cited by 50
Edmondson, S. D., Mastracchio, A., Duffy, J. L., Eiermann, G. J., He, H., Ita, I. E., Leiting, B., Leone, J. F., Lyons, K. A., Makarewicz, A., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.028 · Cited by 48
Large, C. H., Kalinichev, M., Lucas, A., Carignani, C., Bradford, A., Garbati, N., Sartori, I., Austin, N. E., Ruffo, A., Jones, D. N. C., et al. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.02.018 · Cited by 45
Borthwick, A. D., Davies, D. E., Exall, A. M., Hatley, R. J. D., Hughes, J. A., Irving, W. R., Livermore, D. G., Sollis, S. L., Nerozzi, F., Valko, K. L., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060073e · Cited by 45
Clinical Significance of Drug Binding, Protein Binding, and Binding Displacement Drug Interactions
DeVane, C. L., & PharmD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4210 · Cited by 44
The (ir)relevance of plasma protein binding of anticancer drugs
Sparreboom, A. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(01)00157-7 · Cited by 41
Terasaki, T., Pardridge, W. M., & Denson, D. D. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23369-9 · Cited by 41
On the influence of protein binding on pharmacological activity of drugs
Berezhkovskiy, L. M. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21958 · Cited by 40
DasGupta, S., Murumkar, P. R., Giridhar, R., & Yadav, M. R. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.04.003 · Cited by 37
Interspecies Scaling: Role of Protein Binding in the Prediction of Clearance from Animals to Humans
Mahmood, I. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001214 · Cited by 36
Lin, J. H., Hooke, K. F., Yeh, K. C., et al. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23974-x · Cited by 36
Clinical significance of drug binding, protein binding, and binding displacement drug interactions.
Jann, M. W. (2002) · PubMed · Cited by 35
KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo
Hilgert, M., Nöldner, M., Chatterjee, S. S., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00149-4 · Cited by 35
Some features of the kinetics and equilibrium of drug binding to plasma proteins
Berezhkovskiy, L. M. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802503808 · Cited by 32
Feely, J., & Grimm, T. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05579.x · Cited by 26
Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing
Corey, A. E., Al‐Khalidi, H. R., Brezovic, C. P., Marcello, S. R., Parekh, N. J., Taylor, K., & Karam, R. (1999) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199903)20:2<91::aid-bdd162>3.0.co;2-y · Cited by 24
Ito, T., Takahashi, M., Sudo, K., & Sugiyama, Y. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111948 · Cited by 21
Hong, Y., Tang, Y., & Zeng, S. (2008) · Chirality · doi:10.1002/chir.20666 · Cited by 21
Dawidowicz, A. L., Kobielski, M., & Pieniadz, J. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.02.004 · Cited by 18
Rusnak, D. W., Lai, Z., Lansing, T. J., Rhodes, N., Gilmer, T. M., & Copeland, R. A. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.01.103 · Cited by 18
Raboisson, P., Manthey, C. L., Chaikin, M. A., Lattanze, J., Crysler, C. S., Leonard, K. A., Pan, W., Tomczuk, B. E., & Marugán, J. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.03.008 · Cited by 18
LC–MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501)
Buhrow, S. A., REID, J., Jia, L., McGovern, R. M., COVEY, J., Kobs, D. J., GROSSI, I., & Ames, M. M. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.04.031 · Cited by 13
Dawidowicz, A. L., Kobielski, M., & Pieniadz, J. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.011 · Cited by 11
Pharmacology in Drug Discovery: Understanding Drug Response
Kenakin, T. (2011) · doi:10.1016/c2009-0-63928-3 · Cited by 10
Cited by
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., Pires, B., Venkatesh, D. N., Durazzo, A., Lucarini, M., Eder, P., Silva, A. M., et al. (2020) · Molecules · doi:10.3390/molecules25163731 · Cited by 1,560
Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance
Vale, N., Gouveia, M. J., Rinaldi, G., Brindley, P. J., Gärtner, F., & Correia da Costa, J. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02582-16 · Cited by 388
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Metadata
- Authors
- Bohnert, T., & Gan, L.-S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 102
- Issue
- 9
- Pages
- 2953-2994
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2118630726
- Cited by
- 430
- References
- 96
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.